Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in Portugal

Alimera Sciences announced that Alimera Sciences Europe, its Ireland-based European subsidiary, has been granted reimbursement in Portugal for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis affecting the posterior segment. Reimbursement was granted by the National Authority of Medicines and Health Products (INFARMED) with no change to the current label.

“This summer has been a productive one for expanding availability of our noninfectious uveitis indication in our International Segment with it soon to be accessible to patients in all of our direct markets in addition to our key distributor markets,” Rick Eiswirth, President and Chief Executive Officer of Alimera, said in a company news release. “We are looking forward to the third quarter launches in Portugal and France to make Iluvien available for patients suffering from this persistent inflammatory condition and give physicians in these countries a better tool to help their patients see better, longer, with fewer injections.”

The Iluvien sustained release intravitreal implant is indicated in Europe for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies and for prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye (NIU-PS).